Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)

Study Overview
=================
Brief Summary
-----------------
The main objective is to evaluate the interest of the repeated measurement of procalcitonin in patients with pulmonary infection to reduce the duration of antibiotic therapy in comparison with a conventional clinical strategy.

Official Title
-----------------
Reduction of the Duration of Antibiotic Guided by Procalcitonin in Infections Lungs of Hospitalized Elderly: a Randomized

Conditions
-----------------
Lung Infection

Intervention / Treatment
-----------------
* Other: procalcitonine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 80 years Started antibiotics for a chest infection Procalcitonin performed J0 antibiotic treatment Person affiliated to the social security Exclusion Criteria: Patients with a documented infection with germs after Listeria spp, Legionella pneumophilia, Mycobacterium tuberculosis Patients with a documented infection with a virus or parasite (eg hemorrhagic fever, malaria) Patients with endovascular infection associated (endocarditis, pacemaker. Intravascular catheter) Patients with lung abscess associated upon entry Patients with a chronic infection associated Patients with severe immunosuppression (HIV or transplant) Palliative patient Death within 24 hours of admission to nursing units. Presence of antibiotic treatment for chronic infection. Patient under guardianship, curatorship or any other administrative or judicial action or deprivation of the right or freedom Patients hospitalized without their consent

Ages Eligible for Study
-----------------
Minimum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Procalcitonine<br>every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms. | Other: procalcitonine<br>* The recommendations will be based on the level of PCT: 4 levels of advice will be given: It is highly recommended to stop antibiotics if PCT <0.1ng/ml, and the recommended stop if 0.1ng/ml <PCT <0.25 ng / ml. It is recommended to continue treatment if 0.25 ng / ml <PCT ng / ml. Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level.<br>|
| No Intervention: contrôle<br>Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of antibiotic therapy |  | Success of antibiotic therapy within 45 days of inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infection lung elderly patients